Cargando…

LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma

Medulloblastoma (MB) is the most common type of brain cancer in pediatric patients. Body fluid biomarkers will be helpful for clinical diagnosis and treatment. In this study, liquid chromatography–mass spectrometry (LC–MS)-based metabolomics was used to identify specific urine metabolites of MB in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyan, Li, Jing, Hao, Xiaolei, Sun, Haidan, Zhang, Yang, Zhang, Liwei, Jia, Lulu, Tian, Yongji, Sun, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353006/
https://www.ncbi.nlm.nih.gov/pubmed/35936679
http://dx.doi.org/10.3389/fonc.2022.949513
_version_ 1784762777705906176
author Liu, Xiaoyan
Li, Jing
Hao, Xiaolei
Sun, Haidan
Zhang, Yang
Zhang, Liwei
Jia, Lulu
Tian, Yongji
Sun, Wei
author_facet Liu, Xiaoyan
Li, Jing
Hao, Xiaolei
Sun, Haidan
Zhang, Yang
Zhang, Liwei
Jia, Lulu
Tian, Yongji
Sun, Wei
author_sort Liu, Xiaoyan
collection PubMed
description Medulloblastoma (MB) is the most common type of brain cancer in pediatric patients. Body fluid biomarkers will be helpful for clinical diagnosis and treatment. In this study, liquid chromatography–mass spectrometry (LC–MS)-based metabolomics was used to identify specific urine metabolites of MB in a cohort, including 118 healthy controls, 111 MB patients, 31 patients with malignant brain cancer, 51 patients with benign brain disease, 29 MB patients 1 week postsurgery and 80 MB patients 1 month postsurgery. The results showed an apparent separation for MB vs. healthy controls, MB vs. benign brain diseases, and MB vs. other malignant brain tumors, with AUCs values of 0.947/0.906, 0.900/0.873, and 0.842/0.885, respectively, in the discovery/validation group. Among all differentially identified metabolites, 4 metabolites (tetrahydrocortisone, cortolone, urothion and 20-oxo-leukotriene E4) were specific to MB. The analysis of these 4 metabolites in pre- and postoperative MB urine samples showed that their levels returned to a healthy state after the operation (especially after one month), showing the potential specificity of these metabolites for MB. Finally, the combination of two metabolites, tetrahydrocortisone and cortolone, showed diagnostic accuracy for distinguishing MB from non-MB, with an AUC value of 0.851. Our data showed that urine metabolomics might be used for MB diagnosis and monitoring.
format Online
Article
Text
id pubmed-9353006
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93530062022-08-06 LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma Liu, Xiaoyan Li, Jing Hao, Xiaolei Sun, Haidan Zhang, Yang Zhang, Liwei Jia, Lulu Tian, Yongji Sun, Wei Front Oncol Oncology Medulloblastoma (MB) is the most common type of brain cancer in pediatric patients. Body fluid biomarkers will be helpful for clinical diagnosis and treatment. In this study, liquid chromatography–mass spectrometry (LC–MS)-based metabolomics was used to identify specific urine metabolites of MB in a cohort, including 118 healthy controls, 111 MB patients, 31 patients with malignant brain cancer, 51 patients with benign brain disease, 29 MB patients 1 week postsurgery and 80 MB patients 1 month postsurgery. The results showed an apparent separation for MB vs. healthy controls, MB vs. benign brain diseases, and MB vs. other malignant brain tumors, with AUCs values of 0.947/0.906, 0.900/0.873, and 0.842/0.885, respectively, in the discovery/validation group. Among all differentially identified metabolites, 4 metabolites (tetrahydrocortisone, cortolone, urothion and 20-oxo-leukotriene E4) were specific to MB. The analysis of these 4 metabolites in pre- and postoperative MB urine samples showed that their levels returned to a healthy state after the operation (especially after one month), showing the potential specificity of these metabolites for MB. Finally, the combination of two metabolites, tetrahydrocortisone and cortolone, showed diagnostic accuracy for distinguishing MB from non-MB, with an AUC value of 0.851. Our data showed that urine metabolomics might be used for MB diagnosis and monitoring. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353006/ /pubmed/35936679 http://dx.doi.org/10.3389/fonc.2022.949513 Text en Copyright © 2022 Liu, Li, Hao, Sun, Zhang, Zhang, Jia, Tian and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Xiaoyan
Li, Jing
Hao, Xiaolei
Sun, Haidan
Zhang, Yang
Zhang, Liwei
Jia, Lulu
Tian, Yongji
Sun, Wei
LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma
title LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma
title_full LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma
title_fullStr LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma
title_full_unstemmed LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma
title_short LC–MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma
title_sort lc–ms-based urine metabolomics analysis for the diagnosis and monitoring of medulloblastoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353006/
https://www.ncbi.nlm.nih.gov/pubmed/35936679
http://dx.doi.org/10.3389/fonc.2022.949513
work_keys_str_mv AT liuxiaoyan lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT lijing lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT haoxiaolei lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT sunhaidan lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT zhangyang lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT zhangliwei lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT jialulu lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT tianyongji lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma
AT sunwei lcmsbasedurinemetabolomicsanalysisforthediagnosisandmonitoringofmedulloblastoma